These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Waxman AB Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185 [TBL] [Abstract][Full Text] [Related]
13. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Horn EM; Widlitz AC; Barst RJ Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395 [TBL] [Abstract][Full Text] [Related]
15. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. Langleben D; Cacoub P Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744 [TBL] [Abstract][Full Text] [Related]
16. Sitaxsentan in the management of pulmonary arterial hypertension. Benedict NJ Am J Health Syst Pharm; 2007 Feb; 64(4):363-8. PubMed ID: 17299175 [TBL] [Abstract][Full Text] [Related]
17. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445 [TBL] [Abstract][Full Text] [Related]
18. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286 [TBL] [Abstract][Full Text] [Related]
19. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Zacà V; Metra M; Danesi R; Lombardi C; Verzura G; Dei Cas L Ther Adv Respir Dis; 2009 Feb; 3(1):11-4. PubMed ID: 19293198 [TBL] [Abstract][Full Text] [Related]
20. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. O'Callaghan DS; Gaine SP Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]